Entrar/Registro  
INICIO ENGLISH
 
Dermatología Revista Mexicana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Dermatología Revista Mexicana >Año 2015, No. 5


Martínez-Suáre HV
Alopecia areata
Dermatología Rev Mex 2015; 59 (5)

Idioma: Español
Referencias bibliográficas: 38
Paginas: 395-405
Archivo PDF: 596.50 Kb.


Texto completo




RESUMEN

La alopecia areata es una enfermedad crónica que afecta el folículo piloso y algunas veces las uñas. Es de origen multifactorial y puede aparecer a cualquier edad, no tiene distinción de sexo o raza. Se distingue por áreas alopécicas que la mayor parte de las veces son reversibles. Sin embargo, existen formas muy crónicas y resistentes a los tratamientos, que pueden convertirse en un verdadero reto terapéutico para el dermatólogo. Causa gran repercusión psicosocial y puede ser el reflejo de otros trastornos de origen autoinmunitario. No existe un tratamiento específico; sin embargo, algunos medicamentos suelen ser alentadores y dan una respuesta favorable en menor tiempo.


Palabras clave: alopecia areata, tratamiento.


REFERENCIAS

  1. Alkhalifah A, Alsantali A, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology and pathogenesis. J Am Acad Dermatol 2010;62:177-188.

  2. Freyschmidt-Paul P, Rolf H, Kevin JM. Alopecia areata in hair growth and disorders. Vol 1. Chapter: Springer, 2008;15:312-329.

  3. Lundin M, Chawa S. Gender differences in alopecia areata. J Drugs Dermatol 2014;13:409-413.

  4. Goh C, Finkel M, et al. Profile of 513 patients with alopecia areata; associations of diseases sub-types with atopy, autoinmune diseases and positive family history. J Eur Acad Dermatol Venereol 2006;20:1055-1060.

  5. van Baar HM, Perret CM, et al. Abnormal expression of Ki-67 antigen in hair follicle of alopecia areata. Acta Derm Venereol 1992;72:161-164.

  6. Hawit F, Silverberg NB. Alopecia areata in children. Cutis 2008;82:104-110.

  7. Yang S, Yang J, Liu JB, et al. The genetic epidemiology of alopecia areata in china. Br J Dermatol 2004;151:16-23.

  8. Camacho F. Alopecia areata. Cuadros clínicos. Dermatopatología. En: Tricología enfermedades del folículo pilosebáceo. Ed. Biblioteca aula médica, 1996;1:418-420.

  9. Messenger AG, McKillop J, et al. British Association of Dermatologist’s, guidelines for the management of alopecia arata 2012. Br J Dermatol 2012;166:916-926.

  10. Kang H, Wu WY, et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advanced of hair loss. J Invest Dermatol 2010;130:2677-2680.

  11. Amin SS, Sachdeva S. Alopecia areata an update. J Pakistan Assoc Dermatol 2013;23:209-220.

  12. Kavak A, Yesildal N, AH Parlak, et al. Alopecia areata in Turkey: demographic and clinical features. J Europ Acad Dermatol 2008;22:977-981.

  13. Pethukova L, Duvic M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptative inmunity. Nature 2010;466:113-117.

  14. Rodriguez TA, Fernandes KE, National Alopecia Areata registry, et al. Concordance rate of alopecia in identical twins supports both genetic and enviromental factors. J Am Acad Dermatol 2010;62:525-527.

  15. Seyrafi H, Akhiani M, et al. Evalution of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum antibodies in Iranian patients. BMC Dermatol 2005;31:5-11.

  16. Xing L, Dai Z, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reserved by JAK inhibition. Nat Med 2014;20:1043-1049.

  17. Rogers M, Tay YK. Hair disorders. In: Hansen RC, editors. Pediatric Dermatology Philadelphia: Mosby, 2003:525-559.

  18. Bakry OA, Elshazly RM. Oxidative Stress in alopecia areata. Am J Clin Dermatol 2014;15:57-64.

  19. Akar A, Arca E, et al. Antioxidant enzymes and lipid peroxidation in the scalp of patients with alopecia areata. J Dermatol Sci 2002;29:85-90.

  20. Blaumesier B, Van der Goot I. Familial aggregation of alopecia areata. J Am Acad Dermatol 2006;54:627-632.

  21. Wasserman D, Guzman-Sanchez D, et al. Alopecia areata. Int J Dermatol 2007;46:121-131.

  22. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol 2006;55:799-806.

  23. Mane M, Nath AK. Utility of dermoscopy in alopecia areata. Indian J Dermatol 2011;56:407-411.

  24. Bell HK, Ormerod AD, et al. Writing a British Association of Dermatologists clinical guideline: an update on the processand guidance for authors. Br. J Dermatol 2009;160:725-728.

  25. Tan E, Tay YK, Glam YC. A clinical study of childhood alopecia areata in Singapore. Pediatric Dermatol 2002;19:298-301.

  26. Goldsmith LA. Summary of alopecia areata research workshop and future research directions. J Invest Dermatol 1991;96:98-100.

  27. Hoffman R, Eicheler W. Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res 1996;288:153-156.

  28. Tosti A, Loannides D. Alopecias-practical, evaluation and management. Ed. Karger 2015;47:67-75.

  29. Kurosawa M, Nakagawa S, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of sistemyc corticoesteroid therapy for alopecia areata. Dermatology 2006;212:361-365.

  30. Happle R, Kaleveram KJ. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 1980;161:289-297.

  31. Herbst V, Zöller M, et al. Diphenylcyclopropenona treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 2006;16:537-542.

  32. Freyschmidt-Paul P, Hoffmann R. Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 2001;7:213-230.

  33. Ferrando J, Grimalt R. Partial response of severe alopecia areata to cyclosporine. Dermatology 1999;199:67-69.

  34. Phillips MA, Graves JE, et al. Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking ciclosporyne. J Am Acad Dermatol 2005;53:252-255.

  35. Yamamoto S, Jiang H, et al. Stimulation of hair growth by topical application of FK506, a potent immunosuppresive agent. J Invest Dermatol 1994;102:160-164.

  36. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005;52:138-139.

  37. Roseborough I, Lee H, et al. Lack of efficacy of topical latanoprost and bimatoprost dthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009;60:705-706.

  38. Fabbrocini G, Panariello L, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol 2013;27:276-281.



>Revistas >Dermatología Revista Mexicana >Año2015, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019